Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MIMEDX GROUP, INC.MDXG · Entity 5271 | Director | June 18, 2025 | June 23, 2025 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | June 04, 2026 | June 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MIMEDX GROUP, INC.
Report date June 18, 2025 · Filed June 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 212,771 |
Reported balance
After 2025-06-18 transaction · row 1
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 28,609 · Balance 212,771 F1: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders |
Filing footnotes · ownership attribution and instrument terms
F1: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders
Sarepta Therapeutics, Inc.
Report date June 04, 2026 · Filed June 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 214,357 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 16,875 · Balance 214,357 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 10,000 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IGM Biosciences, Inc.
Report date August 14, 2025 · Filed August 14, 2025
Section 16 reporting ended · disclosed 2025-08-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-08-14 transaction · row 1
1 source rowRow 1 · 2025-08-14 · Disposition to issuer · Disposed 22,222 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2025-08-14 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-08-14 · Disposition to issuer · Disposed 330,700 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F2: Prior to the Merger, the shares were held in the name of KBW 2005 Trust for which Reporting Person is the Trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2025-08-14 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-08-14 · Disposition to issuer · Disposed 29,807 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F3: Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2025-08-14 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-08-14 · Disposition to issuer · Disposed 29,806 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F4: Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.
F2: Prior to the Merger, the shares were held in the name of KBW 2005 Trust for which Reporting Person is the Trustee.
F3: Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee.
F4: Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2021 Filed Dec 17, 2021 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.08 | $0.00 |
DisclosureSEC source: 0001209191-21-070084 · doc4.xml · derivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,000 | $10.08 | $50,400.00 |
DisclosureSEC source: 0001209191-21-070084 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 21:36 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 211 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059184 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,061 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:04 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 211 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045193 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,850 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · balance_after: Pursuant to an internal review, the number of shares beneficially owned has been adjusted to correct the number of shares owned directly as compared to the number of shares held by the KBW 2005 Trust for which Reporting Person is Trustee (the "KBW 2005 Trust"). Other than the acquisition of restricted stock units reported in this Form 4, the total number of shares held by the Reporting Person has not changed. Read SEC document |
| May 27, 2021 Filed May 28, 2021 18:24 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 17,056 | $10.26 | $174,994.56 |
DisclosureSEC source: 0001376339-21-000073 · wf-form4_162222625342159.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,427 F1 · kind: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 18:37 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 211 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-024793 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,139 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001209191-21-019671 · doc4.xml · derivative · entry 4 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 5,000 | $85.76 | $428,800.00 |
DisclosureSEC source: 0001209191-21-019671 · doc4.xml · nonDerivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,517 Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,000 | $42.30 | $211,500.00 |
DisclosureSEC source: 0001209191-21-019671 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 5,518 | $0.00 Strike: $87.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018412 · doc4.xml · derivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,518 Underlying: Common Stock · 5,518 shares Expires 2031-03-03 Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018412 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,517 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022. F2 · balance_after: Reflects a correction in the number of shares of common stock reported as beneficially owned by the Reporting Person in prior reports due to an inadvertent error that appeared in the prior reports (an addition of 49 shares). Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:29 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 6,423 | $0.00 Strike: $91.50 | $0.00 |
DisclosureSEC source: 0001209191-21-013585 · doc4.xml · derivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,423 Underlying: Common Stock · 6,423 shares Expires 2031-02-19 F1 · derivative.exercise_date: 1/12 of the shares subject to the option shall vest each month following the Issuer's 2021 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2022 Annual Meeting of Stockholders. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 20:40 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 357 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001699 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,928 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 20:28 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 11,111 | $90.00 | $999,990.00 |
DisclosureSEC source: 0001209191-20-063644 · doc4.xml · nonDerivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,111 F1 · kind: The shares were purchased pursuant to an underwritten public offering of the Issuer's securities. F4 · ownership.nature: The shares are held in the name of Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 20:28 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 11,111 | $90.00 | $999,990.00 |
DisclosureSEC source: 0001209191-20-063644 · doc4.xml · nonDerivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,111 F1 · kind: The shares were purchased pursuant to an underwritten public offering of the Issuer's securities. F3 · ownership.nature: The shares are held in the name of Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 20:28 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 22,222 | $90.00 | $1,999,980.00 |
DisclosureSEC source: 0001209191-20-063644 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,222 F1 · kind: The shares were purchased pursuant to an underwritten public offering of the Issuer's securities. F2 · ownership.nature: The shares are held in the name of KBW 2005 Trust for which Reporting Person is the Trustee. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 20:09 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 26,236 | $6.67 | $174,994.12 |
DisclosureSEC source: 0001376339-20-000123 · wf-form4_160192852097584.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,371 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. Award vests after 12 months. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 19:29 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 357 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053897 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,571 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 1,570 | $64.80 | $101,728.94 |
DisclosureSEC source: 0001209191-20-050353 · doc4.xml · nonDerivative · entry 9 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,214 F9 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $64.475 to $65.245 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 3,351 | $63.58 | $213,043.85 |
DisclosureSEC source: 0001209191-20-050353 · doc4.xml · nonDerivative · entry 8 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,644 F8 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $63.3625 to $64.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 2,791 | $63.06 | $176,003.53 |
DisclosureSEC source: 0001209191-20-050353 · doc4.xml · nonDerivative · entry 7 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,293 F7 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $62.36 to $63.355 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 4,336 | $61.80 | $267,983.88 |
DisclosureSEC source: 0001209191-20-050353 · doc4.xml · nonDerivative · entry 6 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,502 F6 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $61.32 to $62.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 5,033 | $60.86 | $306,332.54 |
DisclosureSEC source: 0001209191-20-050353 · doc4.xml · nonDerivative · entry 5 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,166 F5 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $60.28 to $61.27 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 4,442 | $59.65 | $264,947.53 |
DisclosureSEC source: 0001209191-20-050353 · doc4.xml · nonDerivative · entry 4 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,133 F4 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $59.27 to $60.205 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 5,132 | $58.75 | $301,511.16 |
DisclosureSEC source: 0001209191-20-050353 · doc4.xml · nonDerivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,691 F3 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $58.25 to $59.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 2,367 | $57.75 | $136,691.41 |
DisclosureSEC source: 0001209191-20-050353 · doc4.xml · nonDerivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,559 F2 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $57.24 to $58.235 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 978 | $56.41 | $55,165.07 |
DisclosureSEC source: 0001209191-20-050353 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,192 F1 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $56.00 to $56.985 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 20:33 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 38,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001376339-20-000086 · wf-form4_159674597890737.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,135 F1 · security: On August 5, 2020, based on the closing stock price on that date ($5.90), the Company fixed the number of shares of common stock subject to a previously-granted restricted stock unit award. Award vests upon the earlier of one year or the 2019 annual meeting of shareholders, and will be settled in common stock upon vesting. The grant is exempt under Rule 16b-3. F1 · price: On August 5, 2020, based on the closing stock price on that date ($5.90), the Company fixed the number of shares of common stock subject to a previously-granted restricted stock unit award. Award vests upon the earlier of one year or the 2019 annual meeting of shareholders, and will be settled in common stock upon vesting. The grant is exempt under Rule 16b-3. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 19:31 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 357 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-041279 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,214 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 19:32 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 357 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023472 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,857 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 3,685 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014231 · doc4.xml · derivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 Underlying: Common Stock · 3,685 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014231 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,742 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 17:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $40.27 | $0.00 |
DisclosureSEC source: 0001209191-20-007604 · doc4.xml · derivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: 1/12 of the shares subject to the option shall vest each month following the Issuer's 2020 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 19:04 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 4,503 | $25.61 | $115,319.58 |
DisclosureSEC source: 0001209191-19-060106 · doc4.xml · nonDerivative · entry 4 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,000 F3 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $25.37 to $26.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. F4 · ownership.nature: The shares are held in the name of Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 19:04 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 5,497 | $24.26 | $133,338.53 |
DisclosureSEC source: 0001209191-19-060106 · doc4.xml · nonDerivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,497 F1 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $23.975 to $24.94 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. F4 · ownership.nature: The shares are held in the name of Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 19:04 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 4,503 | $25.61 | $115,319.58 |
DisclosureSEC source: 0001209191-19-060106 · doc4.xml · nonDerivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,000 F3 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $25.37 to $26.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The shares are held in the name of Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 19:04 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 5,497 | $24.26 | $133,338.53 |
DisclosureSEC source: 0001209191-19-060106 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,497 F1 · price: The purchase price reported in column 4 of Table I represents the weighted average purchase price of the shares purchased ranging from $23.975 to $24.94 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The shares are held in the name of Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 21:06 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 62,500 | $16.00 | $1,000,000.00 |
DisclosureSEC source: 0001209191-19-050408 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 21:23 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 12,100 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050253 · doc4.xml · derivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,100 Underlying: Common Stock · 12,100 shares Expires 2029-09-17 F1 · derivative.exercise_date: 1/3 of the shares subject to the option shall vest on September 17, 2020 and an additional 1/36 of the shares subject to the option shall vest monthly thereafter subject to Reporting Person remaining a service provider through each such date. Read SEC document |
| September 06, 2019 Filed Sep 6, 2019 18:13 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 2,500 | $87.98 | $219,950.00 |
DisclosureSEC source: 0001209191-19-048702 · doc4.xml · nonDerivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,667 F2 · price: The shares were purchased in multiple transactions at prices ranging from $87.94 to $88.00, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| September 05, 2019 Filed Sep 6, 2019 18:13 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-19-048702 · doc4.xml · derivative · entry 4 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option to buy shares is fully vested. Read SEC document |
| September 05, 2019 Filed Sep 6, 2019 18:13 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,000 | $7.80 | $39,000.00 |
DisclosureSEC source: 0001209191-19-048702 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 3,213 | $0.00 Strike: $145.48 | $0.00 |
DisclosureSEC source: 0001209191-19-016029 · doc4.xml · derivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213 Underlying: Common Stock · 3,213 shares Expires 2029-03-04 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016029 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,167 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| October 31, 2018 Filed Nov 2, 2018 22:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001209191-18-056986 · doc4.xml · derivative · entry 4 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase shares is fully vested. Read SEC document |
| October 31, 2018 Filed Nov 2, 2018 22:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 10,000 | $131.71 | $1,317,100.00 |
DisclosureSEC source: 0001209191-18-056986 · doc4.xml · nonDerivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,534 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.53 to $131.94, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth herein. Read SEC document |
| October 31, 2018 Filed Nov 2, 2018 22:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 10,000 | $3.96 | $39,600.00 |
DisclosureSEC source: 0001209191-18-056986 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 4,820 | $0.00 Strike: $71.45 | $0.00 |
DisclosureSEC source: 0001209191-18-017788 · doc4.xml · derivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,820 Underlying: Common Stock · 4,820 shares Expires 2028-03-05 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of the Issuer's 2018 Annual Meeting of Stockholders. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 3,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017788 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,534 F1 · shares: Each restricted stock award represents the right to receive one share of common stock and will vest in full on the first year anniversary of the Issuer's 2018 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:45 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020685 · doc4.xml · derivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2027-03-10 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.